What Does the Rise of Real-World Evidence Mean For Pharma?

The COVID-19 pandemic has highlighted the urgent need for real-world evidence to inform decision making. This month’s issue of ISPOR Value and Outcomes Spotlight features a Q&A with Dr. Jennifer Graff, Vice President, Comparative-Effectiveness Research at the National Pharmaceutical Council. Dr. Graff lends her considerable expertise to a discussion on how real-world evidence is being used to give direction to all relevant stakeholders: patients, providers, payers, and policy makers. Access the full interview here.

(Source: ISPOR Value and Outcomes Spotlight, 10/20/20)